China'S New Crown Vaccine Production Capacity Will Reach 610 Million Doses By The End Of The Year. It Is Cost Based And Not For Profit

"It is estimated that by the end of this year, China's annual production capacity of new crown vaccine will reach 610 million doses. Next year, China's annual production capacity of new crown vaccine will be effectively expanded on this basis, so as to ensure the demand for China's new crown vaccine and other countries in the world." On October 20, at the press conference of the joint prevention and control mechanism of the State Council, Zheng Zhongwei, leader of the vaccine research and development team of the joint prevention and control mechanism research team of the State Council and director of the medical and health science and technology development research center of the National Health Commission, said.

Tian Baoguo, deputy director of the Department of social development and science and technology of the Ministry of science and technology, said that at present, China's research and development of new coronal vaccines is generally in a leading position, and 13 vaccines have entered the clinical stage. Among them, inactivated vaccine and adenovirus vector vaccine two technical routes, a total of 4 vaccines have entered the third phase of clinical. As a whole, the four vaccines entering the phase III clinical trial are progressing smoothly. Up to now, a total of 60000 subjects have been vaccinated, and no serious adverse reactions have been reported, which initially shows good safety.

At present, China has carried out emergency use of vaccines in some populations. In this regard, Zheng Zhongwei said that the emergency use of vaccines among high-risk people is a very necessary means to protect their life, health and safety.

In fact, price is also a matter of great concern to the public. In this regard, Zheng Zhongwei pointed out that the rumors on the Internet (the pricing of the new crown vaccine) are all false reports, and most of them are taken out of context. The pricing of new crown vaccine is not based on supply and demand, but on cost. The pricing of new crown vaccine must be within the scope of public acceptance.

By the end of the year, the production capacity could reach 610 million

The National Health Commission said that we should fully understand the arduousness and complexity of China's task of "external defense input and internal anti rebound", always tighten the string of epidemic prevention and control, overcome the paralytic thinking, relaxed mood, war weariness and relaxed mentality, strictly implement the measures of external defense input, firmly curb the spread of local new coronal pneumonia, and prevent the occurrence of clustering epidemic to the greatest extent.

The vaccine will play a key role in curbing the epidemic, and all countries are in the process of research and development. Liu Jingzhen, chairman of Sinopharm group, also said that at present, Beijing Institute of biological products and Wuhan Institute of biological products, affiliated to Sinopharm, are now conducting three phase clinical trials in 10 countries, including the United Arab Emirates, Jordan, Peru, Argentina and Egypt, and more than 50000 people have been vaccinated.

Zheng Zhongwei said that the new crown pneumonia epidemic is a global epidemic of infectious diseases, which is rare in a century. Recently, there have been outbreaks or rebounds of the epidemic in some countries and regions. For China, it is facing enormous pressure on the import of the new crown epidemic.

"In the process of coping with the pressure of overseas import and domestic rebound, some people in China have become high-risk exposed groups in the process of anti epidemic, such as the medical defense personnel on the front line of anti epidemic, the staff at border ports, the staff who have to go to high-risk countries or regions for work reasons to engage in assistance, and the public who maintain the basic operation of the city A total of service security personnel, they are facing the risk of infection. Therefore, it is very necessary to carry out the emergency use of vaccine among these people to protect their life, health and safety. " Zheng Zhongwei said.

Zheng Zhongwei said that the emergency use of China's new crown vaccine is on this basis, in strict accordance with the relevant provisions of the "vaccine administration law of the people's Republic of China" and the "Drug Administration Law of the people's Republic of China", and in accordance with the corresponding procedures. It has been strictly demonstrated and approved at all levels, and also meets the relevant rules of the World Health Organization. After obtaining the approval for the emergency use of the new coronal vaccine in China, China also informed the World Health Organization representative office in China and obtained their approval and support.

Zheng Zhongwei recently introduced that in the process of promoting the emergency use of the new crown vaccine, China carried out a very strict expert demonstration and optimized the emergency use vaccine. China's emergency use of vaccines is strictly in accordance with the relevant provisions of all animal trials and clinical phase I, II trials, and phase I, II trials have also achieved very good safety and immunogenicity indicators. In addition, prior to the official launch of the emergency use of the new coronal vaccine, the preferred vaccine has been approved for three phases of clinical trials. At present, the large-scale population data of the third phase clinical trial in China once again verified the safety and effectiveness of the new crown vaccine emergency use in China.

In addition, in the process of emergency use of new coronal vaccine, our country strictly follows the approved scheme, which is organized and implemented under the premise of voluntary, informed and consent, and has established a very strict work plan for screening of vaccinated personnel, monitoring of adverse reactions, emergency treatment and follow-up after vaccination. Up to now, no serious adverse reactions have been reported in all areas of the country where the use of the vaccine has been reported.

While paying attention to the epidemic situation in China, China is also paying attention to the development of global epidemic situation, so that developing countries can also use and afford safe and effective vaccines.

Zhao Xing, a second level inspector of the International Department of the Ministry of foreign affairs, said that China has joined the "implementation plan for the new coronapneumonia vaccine" jointly sponsored by the WHO Global Alliance for vaccines and immunization. This is also a major move for China to uphold the concept of a community of human health and promote vaccines to become global public goods. Its accession to the implementation plan has also received extensive support from the international community And good reviews. "The Chinese side has solemnly promised that after the research and development of China's vaccine is completed and put into use, it will give priority to providing it to developing countries as a global public product. This is also consistent with the goal and original intention of the implementation plan

Zheng Zhongwei said that it is expected that by the end of this year, the annual production capacity of China's new crown vaccine will reach 610 million doses. Next year, the annual production capacity of China's new crown vaccine will be effectively expanded on this basis, so as to ensure the demand for China's new crown vaccine and other countries in the world.

The price is based on cost

With the approach of the full listing of the vaccine, the public is particularly concerned about whether the new crown vaccine can be included in the medical insurance and how to price it. Various versions of the price have also appeared on the Internet.

Before that, some NPC deputies proposed that "the vaccination of new crown pneumonia vaccine should be included in the full reimbursement of medical insurance".

In response to this proposal, not long ago, the State Medical Security Bureau released the reply to the recommendation No. 9354 of the third session of the 13th National People's Congress (hereinafter referred to as the "reply") on its official website, saying that the financing level of basic medical insurance in China, especially for urban and rural residents, is relatively low. In 2019, the average financing of urban and rural residents' medical insurance is only about 800 yuan, and the number of vaccinated people is large, The total cost is high, which is obviously beyond the affordability of medical insurance fund.

According to the "vaccine management law of the people's Republic of China" implemented on December 1, 2019, vaccines in China are divided into immunization planning vaccine and non immunization planning vaccine. In July 2020, the "Interim Measures for the administration of drug use in basic medical insurance" clearly pointed out that: preventive vaccine is not included in the scope of medical insurance payment.

Previously, Liu Jingzhen, Secretary of the Party committee and chairman of sinopharma group, said in an interview with the media that after the completion of phase III international clinical trials, the new crown inactivated vaccine can enter the approval process, and is expected to be able to go on the market by the end of December this year. Moreover, he disclosed that after the inactivated vaccine is put on the market, the price will not be very high, and it is estimated that it will cost several hundred yuan per injection. If you take two injections, the price should be within 1000 yuan.

Not long ago, Yin Weidong, chairman, President and CEO of Kexing biology, also said that due to different purchasers and procurement scales, the price of vaccines would fluctuate to some extent, but the final price would be at the level of 100 yuan, not exceeding 1000 yuan.

Zheng Zhongwei said that the pricing versions circulated on the Internet are not true. For the price of China's new crown vaccine, first of all, it adheres to the pricing of enterprise entities, and at the same time, it adheres to several basic principles: one is the attribute principle of public goods, and the pricing must not be based on supply and demand, but on cost. The second is to carry out the pricing of new crown vaccine according to the public's willingness and demand for vaccination.

Zheng Zhongwei said that the pricing of the new crown vaccine must be within the acceptable range of the public. He stressed that there are many factors that determine the price of new coronavirus vaccine, including cost, production capacity, vaccination scale, etc., and the costs of different technical routes are also different. For example, the production of inactivated vaccine requires a high-level biosafety workshop, and the cost is relatively high. The cost of vaccines such as adenovirus vector vaccine will be relatively low. With the expansion of production capacity and vaccination scale, the cost will also change.

?